AU2021352378A1 - Methods and compositions for synergistic uptake and retention of small molecule ligands - Google Patents

Methods and compositions for synergistic uptake and retention of small molecule ligands Download PDF

Info

Publication number
AU2021352378A1
AU2021352378A1 AU2021352378A AU2021352378A AU2021352378A1 AU 2021352378 A1 AU2021352378 A1 AU 2021352378A1 AU 2021352378 A AU2021352378 A AU 2021352378A AU 2021352378 A AU2021352378 A AU 2021352378A AU 2021352378 A1 AU2021352378 A1 AU 2021352378A1
Authority
AU
Australia
Prior art keywords
cancer
psma
targeting
agent
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021352378A
Other languages
English (en)
Other versions
AU2021352378A9 (en
Inventor
Neil H. Bander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of AU2021352378A1 publication Critical patent/AU2021352378A1/en
Publication of AU2021352378A9 publication Critical patent/AU2021352378A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2021352378A 2020-10-01 2021-09-28 Methods and compositions for synergistic uptake and retention of small molecule ligands Pending AU2021352378A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063086216P 2020-10-01 2020-10-01
US63/086,216 2020-10-01
PCT/US2021/052271 WO2022072293A2 (en) 2020-10-01 2021-09-28 Methods and compositions for synergistic uptake and retention of small molecule ligands

Publications (2)

Publication Number Publication Date
AU2021352378A1 true AU2021352378A1 (en) 2023-06-08
AU2021352378A9 AU2021352378A9 (en) 2024-10-24

Family

ID=80950778

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021352378A Pending AU2021352378A1 (en) 2020-10-01 2021-09-28 Methods and compositions for synergistic uptake and retention of small molecule ligands

Country Status (7)

Country Link
US (1) US20240000979A1 (https=)
EP (1) EP4221764A4 (https=)
JP (1) JP2023547999A (https=)
AU (1) AU2021352378A1 (https=)
CA (1) CA3194600A1 (https=)
IL (1) IL301842A (https=)
WO (1) WO2022072293A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204477A1 (en) 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
US20240000979A1 (en) * 2020-10-01 2024-01-04 Cornell University Methods and compositions for synergistic uptake and retention of small molecule ligands
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. CHELETARIANS AND BIFUNCTIONAL CONJUGATES
WO2025029946A1 (en) 2023-07-31 2025-02-06 Curium Us Llc [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044616A2 (en) * 2005-10-06 2007-04-19 Xencor, Inc. Optimized anti-cd30 antibodies
WO2018204477A1 (en) * 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
US20240000979A1 (en) * 2020-10-01 2024-01-04 Cornell University Methods and compositions for synergistic uptake and retention of small molecule ligands

Also Published As

Publication number Publication date
WO2022072293A3 (en) 2022-07-21
EP4221764A4 (en) 2025-12-24
AU2021352378A9 (en) 2024-10-24
WO2022072293A2 (en) 2022-04-07
JP2023547999A (ja) 2023-11-15
IL301842A (en) 2023-06-01
US20240000979A1 (en) 2024-01-04
EP4221764A2 (en) 2023-08-09
CA3194600A1 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
US12285503B2 (en) Methods and reagents for tumor targeting with greater efficacy and less toxicity
US20240000979A1 (en) Methods and compositions for synergistic uptake and retention of small molecule ligands
Stillebroer et al. Phase 1 radioimmunotherapy study with lutetium 177–labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma
Cheung et al. Anti-G (D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age.
KR100695383B1 (ko) 암을 치료하기 위한 도세탁셀과 ｒｈｕＭＡｂ ＨＥＲ２의조합제제
CN1878562B (zh) 抗体治疗
US20230364271A1 (en) Methods and compositions for increasing uptake, internalization, and/or retention of small molecule ligands
EP2638397A1 (en) Methods of treating cancer
AU2026201845A1 (en) Methods of treating cancer
WO2021226148A1 (en) Methods for treating pancreatic cancer and other solid tumors
Brouwers et al. Pharmacokinetics and tumor targeting of 131I-labeled F (ab9) 2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies
TW202322855A (zh) 人類表皮生長因子第二型受體疫苗組成物以及套組
JP2023552383A (ja) ペプチド受容体放射性核種療法
KR20130108583A (ko) 암 치료 또는 암 완화 케어용 옥트레오티드 수식 나노 제제
WO2026039321A1 (en) Methods for treating prostate cancer
WO2025250689A1 (en) Combination therapy with angiogenesis protein and immune checkpoint inhibitor with/without chemotherapeutics
Rossi et al. Complete response of severe symptomatic bone marrow metastases from heavily pretreated breast cancer with a 3-weekly trastuzumab schedule. A clinical case
CN112168971A (zh) 抗vegf抗体和pdgf/pdgfr抑制剂在制备治疗表达fgf2肿瘤的药物的应用
HK1189272B (en) Methods of treating cancer

Legal Events

Date Code Title Description
SREP Specification republished